Curis, Inc. (NASDAQ:CRIS)

CAPS Rating: 2 out of 5

A drug discovery and development company that is seeking to leverage its innovative biological signaling pathway drug technologies to create new medicines primarily in the field of cancer.

CRIS News and Commentary

Caps

How do you think CRIS will perform against the market?

Add Stock to CAPS Watchlist

All Players

173 Outperform
11 Underperform
 

All-Star Players

20 Outperform
5 Underperform
 

Wall Street

7 Outperform
0 Underperform
 

Top CRIS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

waderjw (74.77)
Submitted July 14, 2011

They're having good trial runs on their cancer drugs.

louisfool (94.19)
Submitted October 28, 2011

Will underperform until approved. Look for a big pop once that happens.

CRIS VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about CRIS.

Recs

0
Member Avatar SubPrime (< 20) Submitted: 7/29/2014 3:34:54 PM : Outperform Start Price: $1.83 CRIS Score: -83.08

Looking for bump from earnings.

Recs

0
Member Avatar rknapton (43.98) Submitted: 8/6/2013 7:30:28 PM : Underperform Start Price: $4.10 CRIS Score: +132.03

Short. Biotech. Revenues have dried up. Issuing lots of stock and raising debt. Big losses.

Recs

0
Member Avatar RBuskey106 (< 20) Submitted: 3/14/2012 10:40:32 PM : Outperform Start Price: $4.54 CRIS Score: -166.06

Skin cancer drug approved. Working closely with Roche--buyout potential

Leaderboard

Find the members with the highest scoring picks in CRIS.

Score Leader

Broken196

Broken196 (37.69) Score: +221.58

The Score Leader is the player with the highest score across all their picks in CRIS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Broken196 37.69 9/4/2009 Underperform 1Y $2.37 -62.00% +159.40% +221.40 0 Comment
Marshal82 87.10 9/16/2009 Underperform 3Y $2.33 -61.35% +144.22% +205.57 0 Comment
longtermgrowth09 < 20 12/17/2009 Underperform 5Y $2.89 -68.84% +135.16% +204.00 0 Comment
shorttest4 34.24 3/8/2010 Underperform 5Y $3.18 -71.68% +127.88% +199.55 0 Comment
stockjock11 < 20 6/17/2010 Underperform 5Y $1.79 -49.69% +131.89% +181.58 0 Comment
louisfool 94.19 10/28/2011 Underperform 5Y $3.72 -75.96% +102.56% +178.52 2 Comments
boardwalken65 30.96 7/7/2011 Underperform 3M $3.65 -75.50% +92.58% +168.08 0 Comment
EclecticRecluse 80.98 5/4/2011 Underperform 3W $3.72 -75.96% +91.86% +167.81 1 Comment
rknapton 43.98 8/7/2013 Underperform 5Y $4.10 -78.19% +53.84% +132.03 1 Comment
MMCapitalMgmt 99.91 4/14/2016 Underperform 5Y $2.07 -56.80% +25.13% +81.93 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackRWBaird 90.59 10/2/2013 Outperform NS $4.51 -80.17% +54.61% -134.78 0 Comment
TrackRSGoodFCF < 20 4/19/2012 Outperform 5Y $4.85 +7.01% -4.53% +11.54 6/25/2012 @ $5.19 0 Comment
TrackOppenheimer 68.64 12/9/2011 Outperform NS $3.60 -75.16% +109.05% -184.21 0 Comment
tracksummerstree 90.44 10/6/2011 Outperform NS $3.29 -72.82% +127.61% -200.42 0 Comment
trackmlvcapital 22.32 9/22/2011 Outperform NS $3.13 -71.43% +128.24% -199.67 0 Comment
TrackRothCapital 72.64 1/7/2010 Outperform NS $3.59 +1.39% +19.30% -17.90 5/3/2011 @ $3.64 0 Comment
trackthinkequity 89.76 11/24/2009 Outperform NS $2.70 -66.64% +134.57% -201.21 0 Comment
TrackBreanMurray 79.70 10/8/2009 Outperform NS $2.24 -59.79% +144.36% -204.16 0 Comment
TrackEveillard 96.19 6/29/2009 Outperform NS $1.58 -43.00% +184.02% -227.02 2 Comments

Featured Broker Partners